Dr. Reddy's Laboratories, Incorporated

Nephrodi Therapeutics, Inc.

Reddy US Therapeutics, Inc.

Neuropn Therapeutics, LLC

Kareus Therapeutics, Sa

Ish Khanna

Sivaram Pillarisetti

Christopher W Alexander

Jennepalli Sreenu

Anima Baruah

Dibyendu De

Santanu Maitra

Shanavas Alikunju

Janet Klein

Jeff Sands

Indu Dager

Manojit Pal

Javed Iqbal

Ashok Tehim

Uday Saxena

Koteswar Rao Yeleswarapu

Pradip Kumar Sasmal

Vijay Potluri

Thomas Hogberg

Vamsee Krishna Chintakunta

Srinivas Padakanti

Ram Pillarisetti

Mahaboobi Jaleel

Oystein Rist

Lisbeth Elster

Thomas Michael Frimurer

Lars-Ole Gerlach

Indu Dagar

Srinivas Kalleda

Nalivela Kumara Swamy

Deepak Barange

Gayla W Roberts

Lavanya Sagi

Chintakunta Vamsee Krishna

In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of compounds of the class of alkyl carboxylic acids, such as 1,1'-(decane-1,10-diyl)bis(cyclopropane-1-carboxylic acid), pharmaceutical salts or derivatives thereof, and the class of alkyl amides, such as 1,1′-(dodecane-1,12-diyl)bis(cyclopropane-1-carboxamide), pharmaceutical salts or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

Substituted cycloalkanes for managing nephrogenic diabetes insipidus

Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of conditions and diseases mediated by soluble epoxide hydrolase.

Piperidine urea derivatives as soluble epoxide hydrolase inhibitors

In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of 1,1′-(dodecane-1,12-diyl)bis(cyclopropane-1-carboxamide), pharmaceutical salts or derivatives thereof, as described herein, to a subject in need thereof. in certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula (I) or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

The present invention provides a method for treating or preventing a condition or disease in a human or an animal subject wherein the condition or disease is associated with lipoprotein metabolism, the method comprising administering to the subject a composition comprising benzylamine compounds.

Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors

The present invention provides, among other things, new benzylamine compounds, compositions comprising benzylamine compounds, methods of making benzylamine compounds, and methods of using benzylamine compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors

The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. (I) Wherein A, m, R1s, R2, R3, R4 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (&#x3ba;) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS. 

Kappa opioid receptor agonists

The invention is directed to novel substituted benzylamino quinolines, compounds comprising substituted benzylamino quinolines, methods of making substituted benzylamino quinolines, the use of substituted benzylamino quinolines for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism, and the use of substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors.

The invention is directed to novel compounds of Formula I: as well as its stereoisomers and/or pharmaceutically acceptable salts, for the treatment of diabetes and diabetes associated dyslipidemia.

Methods and compositions for treatment of diabetes and dyslipidemia

Methods for the treatment of insulin resistance, diabetes, and/or diabetes associated dyslipidemia by administering niacin and meloxicam are disclosed.

Methods for the treatment of diabetes-associated dyslipdemia

Novel bicyclic compounds of the formula (I), stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided: wherein R, R, m, and n are defined herein.

Biccyclic compounds as GATA modulators

The present invention is directed to a compounds, methods and compositions for making the compounds and methods of treating a variety of diseases and disease states including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan, comprising the administration of new heterocyclic compounds, particularly substituted pyrimidines. The present invention is directed to novel compounds represented by the general formula: 

Pyrimidine compounds, process for their preparation and compositions containing them

The present invention provides, among other things, new bicyclic heterocyclic compounds, compositions comprising these heterocyclic compounds, methods of making the heterocyclic compounds, and methods of using these heterocyclic compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

Growing community of inventors

Alpharetta, GA, United States of America

Ish Khanna